PMID- 30257649
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20240331
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 18
IP  - 1
DP  - 2018 Sep 26
TI  - The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells 
      immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis.
PG  - 929
LID - 10.1186/s12885-018-4817-4 [doi]
LID - 929
AB  - BACKGROUND: Chimeric antigen receptor T (CAR T) cells immunotherapy is rapidly 
      developed in treating cancers, especially relapsed or refractory B-cell 
      malignancies. METHODS: To assess the efficacy and safety of CAR T therapy, we 
      analyzed clinical trials from PUBMED and EMBASE. RESULTS: Results showed that the 
      pooled response rate, 6-months and 1-year progression-free survival (PFS) rate 
      were 67%, 65.62% and 44.18%, respectively. We observed that received 
      lymphodepletion (72% vs 44%, P = 0.0405) and high peak serum IL-2 level (85% vs 
      31%, P = 0.04) were positively associated with patients' response to CAR T cells. 
      Similarly, costimulatory domains (CD28 vs CD137) in second generation CAR T was 
      positively associated with PFS (52.69% vs 33.39%, P = 0.0489). The pooled risks 
      of all grade adverse effects (AEs) and grade >/= 3 AEs were 71% and 43%. Most 
      common grade >/= 3 AEs were fatigue (18%), night sweats (14%), hypotension (12%), 
      injection site reaction (12%), leukopenia (10%), anemia (9%). CONCLUSIONS: In 
      conclusion, CAR T therapy has promising outcomes with tolerable AEs in relapsed 
      or refractory B-cell malignancies. Further modifications of CAR structure and 
      optimal therapy strategy in continued clinical trials are needed to obtain 
      significant improvements.
FAU - Zhou, Hui
AU  - Zhou H
AD  - State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, 
      Sichuan University and Collaborative Innovation Center, No.37, Guoxue Alley, 
      Chengdu, 610041, People's Republic of China.
FAU - Luo, Yuling
AU  - Luo Y
AD  - State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, 
      Sichuan University and Collaborative Innovation Center, No.37, Guoxue Alley, 
      Chengdu, 610041, People's Republic of China.
FAU - Zhu, Sha
AU  - Zhu S
AD  - State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, 
      Sichuan University and Collaborative Innovation Center, No.37, Guoxue Alley, 
      Chengdu, 610041, People's Republic of China.
FAU - Wang, Xi
AU  - Wang X
AD  - State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, 
      Sichuan University and Collaborative Innovation Center, No.37, Guoxue Alley, 
      Chengdu, 610041, People's Republic of China.
FAU - Zhao, Yunuo
AU  - Zhao Y
AD  - State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, 
      Sichuan University and Collaborative Innovation Center, No.37, Guoxue Alley, 
      Chengdu, 610041, People's Republic of China.
FAU - Ou, Xuejin
AU  - Ou X
AD  - State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, 
      Sichuan University and Collaborative Innovation Center, No.37, Guoxue Alley, 
      Chengdu, 610041, People's Republic of China.
FAU - Zhang, Tao
AU  - Zhang T
AD  - State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, 
      Sichuan University and Collaborative Innovation Center, No.37, Guoxue Alley, 
      Chengdu, 610041, People's Republic of China.
FAU - Ma, Xuelei
AU  - Ma X
AD  - State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, 
      Sichuan University and Collaborative Innovation Center, No.37, Guoxue Alley, 
      Chengdu, 610041, People's Republic of China. drmaxuelei@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20180926
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Antigens, CD19)
RN  - 0 (Antigens, CD20)
RN  - 0 (CD19 molecule, human)
RN  - 0 (Receptors, Chimeric Antigen)
SB  - IM
MH  - Antigens, CD19/*immunology
MH  - Antigens, CD20/*immunology
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Immunotherapy
MH  - Immunotherapy, Adoptive/adverse effects/*methods
MH  - Leukemia, B-Cell/immunology/*therapy
MH  - Lymphoma, B-Cell/immunology/*therapy
MH  - Male
MH  - Progression-Free Survival
MH  - Receptors, Chimeric Antigen
MH  - Recurrence
MH  - Survival Analysis
MH  - Treatment Outcome
PMC - PMC6158876
OTO - NOTNLM
OT  - Chimeric antigen receptor T (CAR T) therapy
OT  - Efficacy
OT  - Relapsed or refractory B-cell malignancies
OT  - Safety
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Not applicable. CONSENT FOR 
      PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they 
      have no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral 
      with regard to jurisdictional claims in published maps and institutional 
      affiliations.
EDAT- 2018/09/28 06:00
MHDA- 2018/12/12 06:00
PMCR- 2018/09/26
CRDT- 2018/09/28 06:00
PHST- 2018/07/09 00:00 [received]
PHST- 2018/09/13 00:00 [accepted]
PHST- 2018/09/28 06:00 [entrez]
PHST- 2018/09/28 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2018/09/26 00:00 [pmc-release]
AID - 10.1186/s12885-018-4817-4 [pii]
AID - 4817 [pii]
AID - 10.1186/s12885-018-4817-4 [doi]
PST - epublish
SO  - BMC Cancer. 2018 Sep 26;18(1):929. doi: 10.1186/s12885-018-4817-4.